Efficacy and Safety of Mirtazapine in Fibromyalgia Syndrome Patients: A Randomized Placebo-Controlled Pilot Study

Abstract

Spanish

French

BACKGROUND

Data from an open-label trial suggest that mirtazapine might prove useful in treatment of fibromyalgia syndrome (FMS).

OBJECTIVE

To obtain preliminary efficacy data of mirtazapine for estimation of sample size requirements for a Phase 2 clinical trial in FMS.

METHODS

This 13-week randomized controlled trial compared the effects of mirtazapine 15 mg/day, mirtazapine 30 mg/day, and placebo in 40 patients with FMS. The primary outcomes were change in Pain Visual Analog Scale (PVAS) and proportion of pain responders (≥30% PVAS reduction). Secondary outcomes included scores from the Jenkins Sleep Scale (JSS), Patient Global Impression of Change (PGIC), Fibromyalgia Impact Questionnaire (FIQ), Hamilton Depression Rating Scale (HAM-D), Patient Global Assessment, and self-reported adverse events.

RESULTS

Significant within-group PVAS reductions from baseline were observed in all 3 groups, with the greatest improvement in the mirtazapine 30-mg group (p < 0.005); between-group difference was not significant. The proportion of pain responders did not meet significance criteria (66.67% for mirtazapine 30 mg, 50% for mirtazapine 15 mg, 41.67% for placebo). Significant within-group improvement in JSS scores was seen for mirtazapine 30 mg (p < 0.01) and mirtazapine 15 mg (p < 0.05). Between-group comparison achieved significance for JSS item 3, waking several times per night (p < 0.05). On the PGIC, 72.73% felt better with both mirtazapine dosages compared with 50% for placebo. Within-group FIQ responses indicated improvement in only mirtazapine-treated groups, whereas within-group improvement for HAM-D and Patient Global Assessment was observed in all groups. Based on our findings, the sample size requirement (80% power, 5% type I error) should be 83 per group to detect PVAS change difference between mirtazapine 30 mg and placebo. Common mirtazapine-related adverse events were increased appetite and weight gain.

CONCLUSIONS

Patients with FMS taking mirtazapine exhibited within-group significant improvement in most of the measured outcomes. Between-group analysis was predictably compromised by the small sample size. Mirtazapine was well tolerated. Further study with a larger sample size is likely to be useful.

Get full access to this article

View all access options for this article.

References

1. Russell

, Raphael

. Fibromyalgia syndrome: presentation, diagnosis, differential diagnosis, and vulnerability. CNS Spectr 2008; 13 (suppl 5): 6–11.

2. Wolfe

, Smythe

, Yunus

, The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160–72.

3. Wolfe

, Ross

, Anderson

, Russell

, Hebert

. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19–28.

4. Nisell

, Kosek

. New insights in fibromyalgia: a review. J Clin Rheumatol Musculoskelet Med 2011; 2: 57–65.

5. Zeng

, Chen

, Darmawan

, Rheumatic diseases in China. Arthritis Res Ther 2008; 10: R17. DOI: 10.1186/ar2368

6. Felson

. Comparing the prevalence of rheumatic diseases in China with the rest of the world. Arthritis Res Ther 2008; 10: 106. DOI: 10.1186/ar2369

7. Scudds

, Li

EK-M

, Scudds

. The prevalence of fibromyalgia syndrome in Chinese people in Hong Kong. J Musculoskelet Pain 2006; 14: 3–11. DOI: 10.1300/J094v14n02_02

8. Russell

. The prevalence of the fibromyalgia syndrome in China. J Musculoskelet Pain 2006; 14: 1–2. DOI: 10.1300/J094v14n02_01

9. Gran

. The epidemiology of chronic generalized musculoskeletal pain. Best Pract Res Clin Rheumatol 2003; 17: 547–61. DOI: 10.1016/S1521-6942(03)00042-1

10.

10. Staud

. Biology and therapy of fibromyalgia: pain in fibromyalgia syndrome. Arthritis Res Ther 2006; 8: 208. DOI: 10.1186/ar1950

11.

11. Staud

, Vierck

, Cannon

, Mauderli

, Price

. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001; 91: 165–75.

12.

12. Gracely

, Petzke

, Wolf

, Clauw

. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002; 46: 1333–43. DOI: 10.1002/art.10225

13.

13. Russell

. Neurophysiopathogenesis of fibromyalgia syndrome: a unified hypothesis. Rheum Dis Clin N Am 2009; 35: 421–35.

14.

14. Arnold

. Biology and therapy of fibromyalgia: new therapies in fibromyalgia. Arthritis Res Ther 2006; 8: 212. DOI: 10.1186/ar1971

15.

15. Arnold

, Clauw

, McCarberg

: FibroCollaborative. Improving the recognition and diagnosis of fibromyalgia. Mayo Clin Proc 2011; 86: 457–64. DOI: 10.4065/mcp.2010.0738

16.

16. Recla

. New and emerging therapeutic agents for the treatment of fibromyalgia: an update. J Pain Res 2010; 3: 89–103. DOI: 10.2147/JPR.S6792

17.

17. Boomershine

. Pregabalin for the management of fibromyalgia syndrome. J Pain Res 2010; 3: 81–8. DOI: 10.2147/JPR.S7884

18.

18. Russell

. Fibromyalgia syndrome: approach to management. CNS Spectr 2008; 13 (suppl 5): 27–33.

19.

19. Roth

, Lankford

, Bhadra

, Whalen

, Resnick

. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. Arthritis Care Res 2012; 64: 597–606. DOI: 10.1002/acr.21595

20.

20. Kent

. SnaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355: 911–8. DOI: 10.1016/S0140-6736(99)11381-3

21.

21. de Boer

. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission (abstract). Int Clin Psychopharmacol 1995; 10 (suppl 4): 19–23.

22.

22. Anttila

SAK

, Leinonen

EVJ

. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001; 7: 249–64.

23.

23. Brannon

, Stone

. The use of mirtazapine in a patient with chronic pain. J Pain Symptom Manag 1999; 18: 382–5.

24.

24. Freynhagen

, Muth-Selbach

, Lipfert

, The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr Med Res Opin 2006; 22: 257–64. DOI: 10.1185/030079906X80486

25.

25. Arnold

, Vuadens

, Kuntzer

, Gobelet

, Deriaz

. Mirtazapine decreases the pain feeling in healthy participants. Clin J Pain 2008; 24: 116–9. DOI: 10.1097/AJP.0b013e318159f94a

26.

26. Samborski

, Lezanska-Szpera

, Rybakowski

. Effects of antidepressant mirtazapine on fibromyalgia symptoms. Rocz Akad Med Bialymst 2004; 49: 265–9.

27.

27. Samborski

, Lezanska-Szpera

, Rybakowski

. Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry 2004; 37: 168–70. DOI: 10.1055/s-2004-827172

28.

28. Calis

, Sidawy

, Young

. Clinical analysis of adverse drug reactions. In: Atkinson

Jr , Abernethy

, Daniels

, Dedrick

, Markey

, eds. Principles of clinical pharmacology. 2nd ed. Burlington, MA: Academic Press, 2007: 389–402.

29.

29. Bagby

, Ryder

, Schuller

, Marshall

. The Hamilton Depression Rating Scale: has the gold standard become a lead weight? Am J Psychiatry 2004; 161: 2163–77.

30.

30. Mease

, Arnold

, Choy

, OMERACT Fibromyalgia Working Group: fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol 2009; 36: 2318–29. DOI: 10.3899/jrheum.090367

31.

31. Kim

, Shin

, Kim

, Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci 2008; 62: 75–83. DOI: 10.1111/j.1440-1819.2007.01778.x

32.

32. Theobald

, Kirsh

, Holtsclaw

, Donaghy

, Passik

. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manag 2002; 23: 442–7.

33.

33. Bendtsen

, Jensen

. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 2004; 62: 1706–11.

34.

34. Nutt

. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand 1997; 96 (suppl 391): 31–7.

35.

35. Schreiber

, Bleich

, Pick

. Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects—a possible opioid involvement in severe depression? J Mol Neurosci 2002; 18: 143–9. DOI: 10.1385/JMN:18: 1–2:143

36.

36. Becker

, Schweinhardt

. Dysfunctional neurotransmitter systems in fibromyalgia, their role in central stress circuitry and pharmacological actions on these systems. Pain Res Treat 2012; 2012: 741746. DOI: 10.1155/2012/741746

37.

37. Dworkin

, Turk

, McDermott

, Interpreting the clinical importance of group differences in chronic pain clinical trial: IMMPACT recommendations. Pain 2009; 146: 238–44. DOI: 10.1016/j.pain.2009.08.019

38.

38. Crofford

, Rowbotham

, Mease

, Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 1264–73. DOI: 10.1002/art.20983

39.

39. Wright

, Luedtke

, Van Den Berg

. Duloxetine in the treatment of chronic pain due to fibromyalgia and diabetic neuropathy. J Pain Res 2011; 4: 1–10. DOI: 10.2147/JPR.S12866

40.

40. Roizenblatt

, Neto

NSR

, Tufik

. Sleep disorders and fibromyalgia. Curr Pain Headache Rep 2011; 15: 347–57. DOI: 10.1007/s11916-011-0213-3

41.

41. Schmid

, Wichniak

, Uhr

, Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology 2006; 31: 832–44. DOI: 10.1038/sj.npp.1300923

42.

42. Aslan

, Isik

, Cosar

. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep 2002; 25: 677–9.

43.

43. Schittecatte

, Dumont

, Machowski

, Cornil

, Lavergne

, Wilmotte

. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology 2002; 46: 197–201. DOI: 10.1159/000067812

44.

44. Mease

, Arnold

, Bennett

, Fibromyalgia syndrome. J Rheumatol 2007; 34: 1415–25.

45.

45. Bennett

, Bushmakin

, Cappelleri

, Zlateva

, Sadosky

. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol 2009 36: 1304–11. DOI: 10.3899/jrheum.081090

46.

46. Wheatley

, Moffaert

, Timmerman

, Kremer

CME

, the Mirtazapine-Fluoxetine Study Group. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry 1998; 59: 306–12.

47.

47. Hongsanguansri

, Putthisri

, Zartrungpak

, Kongsakon

. Efficacy and safety of mirtazapine in Thai patients with major depressive disorder. J Psychiatr Assoc Thailand 2001; 46: 179–86.

48.

48. Szegedi

, Schwertfeger

. Mirtazapine: a review of its clinical efficacy and tolerability. Exp Opin Pharmacother 2005; 6: 631–41. DOI: 10.1517/14656566.6.4.631

49.

49. Stimmel

, Dopheide

, Stahl

. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997; 17: 10–21. DOI: 10.1002/j.1875-9114.1997.tb03674.x

50.

50. Watanabe

, Omori

, Nakagawa

, Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs 2010; 24: 35–53. DOI: 10.2165/11319480-000000000-00000

51.

51. Sakata

, Yoshimatsu

, Kurokawa

. Hypothalamic neuronal histamine: implications of its homeostatic control of energy metabolism. Nutrition 1997; 13: 403–11.

52.

52. Halford

JCG

, Harrold

, Boyland

, Lawton

, Blundell

. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007; 67: 27–55.

53.

53. Arnold

, Burns

KEA

, Adhikari

NKJ

, The design and interpretation of pilot trials in clinical research in critical care. Crit Care Med 2009; 37 (suppl): S69–S74. DOI: 10.1097/CCM.0b013e3181920e33